Evidence map›Paper›PMID 37526994›Full record

ArticleJournal of synchrotron radiation2023

Fast, automated, continuous energy scans for experimental phasing at the BioMAX beamline.

Ishkhan Gorgisyan, Paul Bell, Michele Cascella, Mikel Eguiraun, Áureo Freitas, Julio Lidon-Simon, Jie Nan, Carla Takahashi, Hamed Tarawneh, Thomas Ursby and 1 more

Abstract read
In one paragraph

Article in Journal of synchrotron radiation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ishkhan GorgisyanMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.
Paul BellMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.
Michele CascellaMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.ORCID 0000-0003-2091-2501
Mikel EguiraunMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.
Áureo FreitasMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.ORCID 0000-0001-5465-2504
Julio Lidon-SimonMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.
Jie NanMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.ORCID 0000-0003-1054-5082
Carla TakahashiMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.
Hamed TarawnehMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.ORCID 0000-0002-7371-7200
Thomas UrsbyMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.ORCID 0000-0001-7371-5507
Ana GonzalezMAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.ORCID 0000-0001-8858-399X

Funding

Novo Nordisk NNF17CC0030666Vetenskapsrådet 2018-07152VINNOVA 2018-04969
6 · The paper itself

Abstract

In X-ray macromolecular crystallography (MX), single-wavelength anomalous dispersion (SAD) and multi-wavelength anomalous dispersion (MAD) techniques are commonly used for obtaining experimental phases. For an MX synchrotron beamline to support SAD and MAD techniques it is a prerequisite to have a reliable, fast and well automated energy scan routine. This work reports on a continuous energy scan procedure newly implemented at the BioMAX MX beamline at MAX IV Laboratory. The continuous energy scan is fully automated, capable of measuring accurate fluorescence counts over the absorption edge of interest while minimizing the sample exposure to X-rays, and is about a factor of five faster compared with a conventional step scan previously operational at BioMAX. The implementation of the continuous energy scan facilitates the prompt access to the anomalous scattering data, required for the SAD and MAD experiments.

Indexed as

continuous energy scanflying scanMAD SAD phasingmotion synchronizationMX beamline

Identifiers

PMID37526994
PMCPMC10481266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.